Natalizumab has demonstrated efficacy in multiple sclerosis (MS), but is associated with increased risk of progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection caused by the JC virus. At the time of natalizumab's reapproval in 2006, the estimated risk of PML was 1:1,000 (95% confidence interval 0.2-2.80) over 17.9 months of treatment. 1 Since then, 3 risk factors for natalizumab-related PML have emerged 2 : 1) cumulative exposure to natalizumab, with risk increasing up to 3 years, after which risk appears to plateau; 2) previous treatment with cytotoxic or immunosuppressive (IS) drugs 3 ; and 3) prior history of JCV infection, as indicated by the presence of JCV antibodies. Using a 2-step ELISA assay for anti-JCV antibodies, Gorelik et al. 4 reported a 53.6% incidence of anti-JCV antibodies in patients with MS; the false-negative rate was 2.5%. To date, 28 natalizumab-related PML cases had blood specimens available 1 year or more prior to the development of PML. Using this assay, all 28 patients were seropositive, which is highly statistically significant ( p ϭ 3.21 ϫ 10 Ϫ8 ). 5 This assay is now clinically available in the United States and Europe.
Methods. We used these 3 risk factors to estimate specific risks of PML during natalizumab treatment (appendix e-1 on the Neurology ® Web site at www.neurology.org). The incidence of PML with different exposure durations and the effect of prior IS was derived from the June 2011 natalizumab-PML report provided by the Medical Information and Medical Affairs Neurology groups at Biogen Idec. 3 A total of 42% of patients with PML had prior IS, while an estimated 20.3% of all natalizumab-treated patients have prior IS, 3 yielding a risk ratio of 2.07 with prior IS, and 0.73 without prior IS. Based on the false-negative rate, we assumed that 2.5% of patients with false-negative JCV antibody results had the same risk of PML as those testing positive on JCV serology.
For the overall risk of PML in seropositive patients, the following formula was used: [overall risk
of PML] ϫ [prior IS adjustment]/[JCV seroprevalence]. For example, the overall risk for a seropositive patient with prior chemotherapy is (1.66 per 1,000) ϫ 2.07/0.536 ϭ 6.41 per 1,000, or 1 in 156.
In seronegative patients, it was assumed that only those with false-negative serology are at risk for PML:
For example, the overall risk for a seronegative patient without prior chemotherapy is (1.66 per 1,000) ϫ 0.73 ϫ 0.025/0.536 ϭ 0.056 per 1,000, or 1 in 17,693. For patients with greater than 24 months treatment, the overall risk of PML was 3.05/1,000, and for less than 24 months treatment, it was 0.57/1,000. 3
Results. Using the above calculations, a table was created to describe the risk of PML in each patient subgroup according to the 3 risk factors. The table indicates that the risk of natalizumab-related PML varies widely, depending upon these 3 risk factors, suggesting that this simple classification scheme will be clinically useful. The prevalence estimates of PML rely upon voluntary registries, which likely underestimate the cases of PML. Therefore, our calculated risks may be an underestimate of the true risks of PML, although the proportional differences in risk between patient groups would remain unchanged.
The risk of PML in patients with newly acquired JCV infection is not reflected in the risk calculations. Assuming the rate of seroconversion is low, this would not substantially shift estimates of risk.
Discussion.
We have found this table helpful both to stratify and estimate the risk of PML in individual patients, and to explain the risk to patients and their families. Generally, we have found that patients have difficulty putting these numeric risks into real-world context. Many patients find it useful to compare the risk of natalizumab-associated PML with more familiar catastrophic events. For example, the lifetime risk of dying from an airplane crash is reported to be 1:20,000; from drowning, 1:8,942; from fire or smoke exposure, 1:1,116:, and from an automobile accident, 1:100. 6 Importantly, the information in the table is only one factor used for treatment decisions. Other factors The numbers in the table will shift with time and new PML cases. Using the online supplemental file, revised risk estimates can be derived using updated prevalence rates. Hopefully, additional risk factors and biological markers-genetic, viral, or immunologic-will be developed to further predict natalizumab-associated PML in the individual patient. Disclosure: Dr. Fox has received speaker honoraria from Biogen Idec and Teva Pharmaceuticals; has served as a consultant for Avanir, Biogen Idec, Genentech, Inc., and Novartis; has served on clinical trial advisory committees for Biogen Idec; has received/receives research support from the National Multiple Sclerosis Society; and serves on the editorial boards of Neurology ® and Multiple Sclerosis. Dr. Rudick has received speaker honoraria or consulting fees from Biogen Idec, Wyeth, Genzyme Corporation, and Novartis; royalty payments from Informa Healthcare, and research support from the NIH (NINDS, NCRR); and serves on the editorial board of Lancet Neurology.
